When did the Entera Bio (ENTX) insider share purchase by Haya Taitel occur?

The insider purchase took place on February 10, 2026. This date is listed as the transaction date in Table I of the Form 4, covering 7,500 ordinary shares of Entera Bio bought in multiple trades at prices between $1.47 and $1.4799.

Director Haya Taitel buys 7,500 Entera Bio (ENTX) shares around $1.48

Filing Impact

(Neutral)

Filing Sentiment

(Positive)

Form Type

Rhea-AI Filing Summary

Entera Bio Ltd. director Haya Taitel reported buying 7,500 ordinary shares on February 10, 2026. The Form 4 shows a purchase at a weighted average price of $1.48 per share, executed through multiple trades between $1.47 and $1.4799, with the holding reported as direct ownership.

Insider Trade Summary

Net Buyer: 7,500 shares

Net Buy 1 txn

Insider Taitel Haya

Role Director

Bought 7,500 shs ($11K)

Type	Security	Shares	Price	Value
Purchase	Ordinary Shares, par value NIS 0.0000769 per share	7,500	$1.48	$11K

Holdings After Transaction: Ordinary Shares, par value NIS 0.0000769 per share — 0 shares (Direct)

Footnotes (1)

F1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.47 to $1.4799 inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/11/2026 - 08:47 AM

FAQ

What insider transaction did Entera Bio (ENTX) report for director Haya Taitel?

Entera Bio reported that director Haya Taitel bought 7,500 ordinary shares. The transaction occurred on February 10, 2026 and was reported on a Form 4 insider filing, indicating a purchase rather than a sale and classed as directly owned shares.

At what price did Haya Taitel purchase Entera Bio (ENTX) shares?

The filing reports a weighted average purchase price of $1.48 per share. A footnote adds that the 7,500 ordinary shares were bought in multiple trades, with individual prices ranging from $1.47 to $1.4799 per share on the transaction date.

Is the Haya Taitel Entera Bio (ENTX) transaction a buy or a sell?

The transaction is a buy. The Form 4 lists transaction code “P,” which denotes a purchase, for 7,500 ordinary shares of Entera Bio at a weighted average price of $1.48, executed across several trades within a narrow price range.

How are the purchased Entera Bio (ENTX) shares held by Haya Taitel?

The Form 4 classifies the 7,500 ordinary shares as directly owned. In Table I, the ownership form for the position following the reported purchase is marked “D” for direct, and no indirect holding entity or special ownership structure is noted.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Taitel Haya

(Last)

(First)

(Middle)

KIRYAT HADASSAH, MINRAV BUILDING

5TH FLOOR

(Street)

JERUSALEM

9112002

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Entera Bio Ltd. [ ENTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares, par value NIS 0.0000769 per share	02/10/2026		P		7,500	A	$1.48⁽¹⁾	$98,479	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.47 to $1.4799 inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Dana Yaacov-Garbeli, Attorney-in-Fact	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR